NIMble innovation — a networked model for public antibiotic trials

Glover, Rebecca E.; Singer, Andrew C. ORCID: https://orcid.org/0000-0003-4705-6063; Roberts, Adam P.; Kirchhelle, Claas. 2021 NIMble innovation — a networked model for public antibiotic trials. The Lancet Microbe, 2 (11), e572. 8, pp. 10.1016/S2666-5247(21)00182-8

Before downloading, please read NORA policies.

Preview

Text N531248JA.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (501kB) | Preview

Abstract/Summary

Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model's benefits for unblocking the public and private antibiotic pipeline.

Item Type:	Publication - Article
Digital Object Identifier (DOI):	10.1016/S2666-5247(21)00182-8
UKCEH and CEH Sections/Science Areas:	Pollution (Science Area 2017-)
ISSN:	2666-5247
Additional Information. Not used in RCUK Gateway to Research.:	Open Access paper - full text available via Official URL link.
NORA Subject Terms:	Medicine
Date made live:	15 Oct 2021 10:21 +0 (UTC)
URI:	https://nora.nerc.ac.uk/id/eprint/531248

Actions (login required)

View Item

Document Downloads

More statistics for this item...